Clinical trialNCT05651932RecruitingPhase 1Interventional

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

SponsorK36 Therapeutics, Inc.Enrollment165Multiple MyelomaMyelomaMyeloma Multiple

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

University Health Network (uhn) - Princess Margaret Cancer Centre (princess Margaret Hospital)
Toronto, Ontario, Canada
Suzanne Trudel, MSc, MD
Recruiting

France

Universitaire de Lille
Villeneuve-d'Ascq, France, France
Salomon Manier, MD
Recruiting
Centre Hospitalier Universitaire de Nantes (chu de Nantes) - Hotel-Dieu
Nantes, France
Cyrille Touzeau, MD
Recruiting
Centre Hospitalier Universitaire de Poitiers (chu de Poitiers)
Poitiers, France
Xavier Leleu, MD
Recruiting
Institut Universitaire Du Cancer de Toulouse - Oncopole
Toulouse, France
Pierre Bories, MD
Recruiting

Spain

Clínica Universidad de Navarra
Pamplona, Navarre, Spain
Paula Rodriguez, MD, PhD
Recruiting
Hospital Clã-Nic de Barcelona
Barcelona, Spain
Laura Rosinol, MD, PhD
Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain
Joaquín Martínez López, MD
Recruiting
Instituto de Investigacion Biomedica de Salamanca (ibsal)
Salamanca, Spain
Maria-Victoria Mateos Manteca, MD, PhD
Recruiting

United States

Ucsf Medical Center - Hematology and Blood and Marrow Transplant Clinic
San Francisco, California, United States
Alfred Chung, MD
Recruiting
Mayo Clinic Hospital - Florida
Jacksonville, Florida, United States
Vivek Roy, MD
Recruiting
University of Miami Don Soffer Clinical Research Center
Miami, Florida, United States
Dickran Kazandjian, MD
Not, yet, recruiting
the Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
Sagar Lonial, MD, FACP
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Yuxin Liu, MD
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Andrew Yee, MD
Recruiting
Mayo Clinic - Transplant Center - Rochester
Rochester, Minnesota, United States
David Dingli, MD, PhD
Recruiting
Hackensack University Medical Center
Hackensack, New Jersey, United States
David S Siegel, MD, PhD
Recruiting
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Saad Usmani, MD, FACP
Recruiting
Atrium Health, Levine Cancer Institute
Charlotte, North Carolina, United States
Cindy Varga, MD
Recruiting
Duke University Hospital
Durham, North Carolina, United States
Cristina Gasparetto, MD
Recruiting
Cleveland Clinic - Taussig Cancer Institute
Cleveland, Ohio, United States
Louis Williams, MD
Not, yet, recruiting
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Ed Stadtmauer, MD
Recruiting
Medical University of South Carolina (musc) - Hollings Cancer Center
Charleston, South Carolina, United States
Anthony Dominick, DO
Recruiting
Tennessee Oncology
Nashville, Tennessee, United States
Jesus Berdeja, MD
Recruiting
University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas, United States
Aimaz Afrough, MD
Recruiting
Northwest Medical Specialties
Tacoma, Washington, United States
Jorge Chaves, MD
Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cohort A1 & A2: KTX-1001Cohort B1 & B2: KTX-1001+MezigdomideCohort C1 & C2: KTX-1001 + CarfilzomibCohort D: KTX-1001+ pomalidomide

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 22 Feb 2023
Primary completion: 31 Dec 2027
Completion: 30 Jun 2028
Last update posted: 18 Aug 2026
Registered enrollment: 165
Registry id: NCT05651932

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.